TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11084060
Drug: Tacrolimus (TAC)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (TAC) therapy
Study: 1348159
Drug: Sulfasalazine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (4 g daily)
Study: 30056410
Drug: Instrumental Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instrumental Group (self-treatment using an Occipivot cushion)
Study: 24778002
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative therapy (OMTh) + conventional care
Study: 20190350
Drug: 9% CHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9% CHO solution
Study: 12443833
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogens 0.625 mg/day (ERT)
Study: 12443833
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) with 5 mg/day continuous medroxyprogesterone
Study: 8562470
Drug: slow-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: slow-release verapamil 240 mg once daily
Study: 8562470
Drug: captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: captopril 25 mg daily (for nonresponders)
Study: 2292349
Drug: Miglitol 100
Normalized name: miglitol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol 100 mg t.i.d. for 8 weeks
Study: 9675626
Drug: Tramadol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (100 mg/2 mL)
Study: 9675626
Drug: Pentazocine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (30 mg/mL)
Study: 2572618
Drug: Midaglizole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midaglizole (200 mg)
Study: 28185899
Drug: Lurasidone adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone adjunctive therapy (20-80 mg/day) for 6 weeks
Study: 25305567
Drug: Coad (MenACWY‐TT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coad (MenACWY‐TT co-administered with DTaP)
Study: 23566694
Drug: Systemic enzyme
Normalized name: alpha-D-galactosidase enzyme Chewable Tablet [Beano]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic enzyme therapy (twice-daily dose for 5 days starting from the first postoperative day)
Study: 21285229
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron supplementation with 50 mg elemental iron for 14 weeks
Study: 19125084
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with GaAlAs, wavelength 830 nm, power 100 mW, dose 4 J/cm, for 5 days
Study: 16633139
Drug: Reboxetine 8‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine 8‐10 mg per day
Study: 16633139
Drug: Citalopram 20‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20‐40 mg per day
Study: 8106898
Drug: Thrombolytic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic and anti-platelet therapy
Study: 3605188
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of NPH and tolazamide
Study: 23361101
Drug: Ephedra-free dietary
Normalized name: Ephedra sinica root
DrugBank: Ephedra sinica root (DB01363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedra-free dietary supplements (four types), ingested three times daily for 3 days
Study: 23361101
Drug: Ephedra-free dietary
Normalized name: Ephedra sinica root
DrugBank: Ephedra sinica root (DB01363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedra-free dietary supplements (four types)
Study: 23361101
Drug: Ephedra-free dietary
Normalized name: Ephedra sinica root
DrugBank: Ephedra sinica root (DB01363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedra-free dietary supplements (two types)
Study: 23361101
Drug: Ephedra-free dietary
Normalized name: Ephedra sinica root
DrugBank: Ephedra sinica root (DB01363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedra-free dietary supplements
Study: 18445111
Drug: Alcohol (male:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (male: 0.6 g/kg, female: 0.5 g/kg)
Study: 17135158
Drug: Dysmo-off (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dysmo-off (5 g twice daily for 4 days, one day prior to and three days after menstruation)
Study: 17135158
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (50 mg twice daily for 4 days, one day prior to and three days after menstruation)
Study: 10742724
Drug: Indinavir alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir alone (800 mg q8h)
Study: 10742724
Drug: Zidovudine alone
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine alone (200 mg q8h)
Study: 8650247
Drug: Combined use
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined use of other agents along with vitamin D
Study: 6352611
Drug: 1-g intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-g intramuscular ceftazidime
Study: 6352611
Drug: 2-g intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-g intramuscular ceftazidime (twice or thrice daily)
Study: 26039494
Drug: Animal-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal-assisted therapy
Study: 30204523
Drug: Higher-intensity taper
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-intensity taper (5.9% increase in intensity)
Study: 30204523
Drug: Lower-intensity taper
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-intensity taper (8.5% decrease in intensity)
Study: 18059577
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.1 g.kg(‐1).d(‐1))
Study: 11158747
Drug: Amprenavir (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amprenavir (1,200 mg twice a day for 4 days, followed by a washout period, then amprenavir plus rifabutin (300 mg QD) for 10 days)
Study: 11158747
Drug: Amprenavir (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amprenavir (1,200 mg twice a day for 4 days, followed by a washout period, then amprenavir plus rifampin (600 mg QD) for 4 days)
Study: 9039154
Drug: Clonidine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.15 mg + captopril 6.25 mg
Study: 9039154
Drug: Captopril 6.25
Normalized name: captopril 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 6.25 mg + placebo
Study: 8316771
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Hydroxychloroquine + Dapsone)
Study: 28214093
Drug: Education for
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education for Christian church leaders on scientific, religious, and cultural aspects of male circumcision (1-day seminar and bi-weekly meetings during the campaign)
Study: 26196084
Drug: 400 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms buccal misoprostol 3 hours preoperatively
Study: 26196084
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral mifepristone during dilator placement
Study: 23781269
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (5 days)
Study: 17716735
Drug: Oral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation of vitamin C (180 mg), vitamin E (30 mg), zinc (22.5 mg), copper (1 mg), lutein (10 mg), zeaxanthin (1 mg), and astaxanthin (4 mg) daily for 12 months (T-AMD group)
Study: 14725410
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine, Avaxim 80 paediatric, given as a two-dose schedule with the second dose at 6 months
Study: 14725410
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine, Avaxim 80 paediatric, given as a two-dose schedule with the second dose at 12 months
Study: 14725410
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine, Avaxim 80 paediatric, given as a two-dose schedule with the second dose at 18 months
Study: 10950003
Drug: Topical 10
Normalized name: urea topical 10% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 10 percent phenylephrine
Study: 29223599
Drug: bupropion hydrochloride
Normalized name: Bupropion Hydrochloride
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupropion hydrochloride sustained-release
Study: 24796977
Drug: CHO7% (7%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO7% (7% carbohydrate solution)
Study: 24796977
Drug: lowCHO1.5% (1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: lowCHO1.5% (1.5% carbohydrate solution)
Study: 20177856
Drug: Intravenous carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous carbohydrate administration (glucose, magnesium, potassium)
Study: 20177856
Drug: Oral carbohydrate
Normalized name: omega-3 carboxylic acids Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral carbohydrate administration (specifically composed solution)
Study: 19040000
Drug: Alen +
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alen + calcium group (n = 74) receiving Alen 10 mg once a day and castrate D 600 0.6 g once a day for 24 weeks
Study: 19040000
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 66) receiving castrate D 600 0.6 g once a day for 24 weeks
Study: 16330203
Drug: Intravenous replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous replacement fluid therapy (FT)
Study: 14576555
Drug: 1 mug/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mug/ml fentanyl
Study: 14576555
Drug: 0.0625% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0625% levobupivacaine and 1 mug/ml fentanyl
Study: 8916625
Drug: Behavioral couples
Normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral couples therapy (BCT)
Study: 1602291
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (75 mg d-1, Group I, n = 4)
Study: 1602291
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin (Group II, n = 5)
Study: 27169837
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg quercetin‐3‐O‐glucoside
Study: 27169837
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg quercetin‐3‐O‐glucoside
Study: 27169837
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg quercetin‐3‐O‐glucoside
Study: 27169837
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg quercetin‐3‐O‐glucoside
Study: 27169837
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg quercetin‐3‐O‐glucoside (control)
Study: 21049059
Drug: Paromomycin (PM)
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paromomycin (PM) at 15 mg/kg/day for 21 days
Study: 21049059
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate (SSG) at 20 mg/kg/day for 30 days
Study: 21049059
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PM and SSG
Study: 11788911
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with cisplatin, fluorouracil (5‐FU), l‐leucovorin and interferon alpha2b (PFL‐IFN)
Study: 10438259
Drug: Gemfibrozil (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (1200 mg per day)
Study: 2147914
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg ticlopidine twice daily
Study: 2147914
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg aspirin every third day plus 75 mg dipyridamole three times daily
Study: 2147914
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg xanthinol nicotinate three times daily
Study: 6996931
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg dipyrone
Study: 22428464
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg aspirin
Study: 29036255
Drug: tavaborole 5%
Normalized name: TAVABOROLE 5% SOLN,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: tavaborole 5% solution
Study: 28472067
Drug: MVA85A vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA85A vaccine
Study: 19332190
Drug: Clopidogrel administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel administration in patients with STEMI
Study: 19332190
Drug: Clopidogrel administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel administration in patients with non-STEMI
Study: 19332190
Drug: Clopidogrel administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel administration in patients with unstable angina
Study: 19332190
Drug: Clopidogrel administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel administration in patients <65 years old receiving fibrinolytic therapy for STEMI
Study: 19332190
Drug: Clopidogrel administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel administration in patients 65 to 74 years old receiving fibrinolytic therapy for STEMI
Study: 19332190
Drug: Clopidogrel administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel administration in patients >75 years old receiving fibrinolytic therapy for STEMI
Study: 15785163
Drug: Trandolapril (angiotensin-converting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (angiotensin-converting enzyme inhibitor)
Study: 15259398
Drug: Nicotine polacrilex
Normalized name: Nicotine Polacrilex
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine polacrilex (2 mg)
Study: 15259398
Drug: Cholinesterase inhibitor
Normalized name: Acetylcholinesterase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitor (THA)
Study: 7605022
Drug: Propofol (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (target concentrations of 2, 4, or 6 micrograms/ml) with alfentanil (initial target concentration 50 ng/ml)
Study: 7605022
Drug: Alfentanil (plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (plasma concentrations increasing from 10 to 150 ng/ml)
Study: 28428110
Drug: Peak flow
Normalized name: Peak Flow Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak flow categorized as 10 to 14.9 ml/s
Study: 28428110
Drug: Peak flow
Normalized name: Peak Flow Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak flow categorized as less than 10 ml/s
Study: 28428110
Drug: Peak flow
Normalized name: Peak Flow Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak flow categorized as 15 or greater ml/s
Study: 28428110
Drug: Peak flow
Normalized name: Peak Flow Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak flow categorized as 10 to 14.9 ml/s (multivariable analysis)
Study: 26168262
Drug: Family Focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family Focused Therapy for Clinical High‐Risk (FFT‐CHR), an 18-session intervention consisting of psychoeducation and training in communication and problem solving.
Study: 26168262
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (FFT-CHR and control).
Study: 23904409
Drug: Combined glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined glucocorticoid receptor/mineralocorticoid receptor stimulation with prednisolone
Study: 21734467
Drug: Control (licensed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (licensed quadrivalent meningococcal polysaccharide vaccine and hepatitis B vaccine)
Study: 19388866
Drug: guaraná 75
Normalized name: GUARANA
Approvals — FDA: no, EMA: no, PMDA: no
Description: guaraná 75 mg daily p.o.
Study: 16626411
Drug: Fail-first algorithm
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fail-first algorithm on conventional antipsychotics (CON)
Study: 16626411
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment requiring switching
Study: 8936399
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of caffeine in coffee
Study: 6854139
Drug: DMSO (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMSO (30 ml, 70% solution)
Study: 6854139
Drug: Sulindac (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (400 mg, orally)
Study: 31820304
Drug: 10-mg orodispersible
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg orodispersible tablet (DT1)
Study: 31820304
Drug: 10-mg oral
Normalized name: rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-mg oral solution (SOL)
Study: 31820304
Drug: 10-mg orodispersible
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg orodispersible tablet without water (DT2dry)
Study: 31820304
Drug: 10-mg orodispersible
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg orodispersible tablet with water (DT2water, reference formulation)
Study: 31663285
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg once daily for 16 days)
Study: 31663285
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg once daily for 16 days)
Study: 20232605
Drug: Telephone counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone counseling along with a home telemonitoring scale and instructions to self‐weigh daily
Study: 15998777
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (0.5 g, then 0.25 g, 6 wk each)
Study: 15998777
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone starting with 0.1 g/d, then tapering the dose by 0.01 g/wk
Study: 15998777
Drug: Intravenous glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucocorticoid therapy
Study: 12776578
Drug: Ebastine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine (10 mg once daily)
Study: 12027065
Drug: Fexofenadine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine (60 mg, twice daily)
Study: 8603453
Drug: ThioTEPA 30
Normalized name: thiotepa 30 mg INJECTION VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ThioTEPA 30 mg/30 ml distilled water
Study: 8603453
Drug: ThioTEPA 30
Normalized name: thiotepa 30 mg INJECTION VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ThioTEPA 30 mg/60 ml distilled water
Study: 8603453
Drug: ThioTEPA 60
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ThioTEPA 60 mg/30 ml distilled water
Study: 8603453
Drug: ThioTEPA 60
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ThioTEPA 60 mg/60 ml distilled water
Study: 54579
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (5000 units of sodium heparin every 12 hours for 5 days)
Study: 54579
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin treatment
Study: 31493728
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) anticoagulants (Vitamin K antagonists or Low Molecular Weight Heparin)
Study: 25377272
Drug: CNI therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNI therapy after belatacept withdrawal
Study: 25377272
Drug: MMF monotherapy
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF monotherapy after belatacept withdrawal
Study: 2526419
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (standard doses)
Study: 2526419
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (third dose late, >7 months after first dose)
Study: 2526419
Drug: Various schedules
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various schedules of dose timing (early/late second and third doses)
Study: 11952465
Drug: 50 microgs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microgs of oral misoprostol, repeated every 4 h to a maximum of 5 doses.
Study: 11952465
Drug: 100 microgs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microgs of oral misoprostol, repeated every 4 h to a maximum of 5 doses.
Study: 11952465
Drug: Preference for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preference for oral inducing agent if another induction is needed.
Study: 23717118
Drug: Korean Red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean Red Ginseng (KRG) in CT genotype of G protein beta 3 gene
Study: 23717118
Drug: Korean Red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean Red Ginseng (KRG) in Trp64/Arg genotype of beta 3 adrenergic receptor gene
Study: 2203140
Drug: Multimodal tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal tumor therapy
Study: 364910
Drug: Cimetidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1 g/day) for 28 days
Study: 21625183
Drug: Trastuzumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab treatment continued after diagnosis of BM